Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD of BriaCell Therapeutics Corp. from Q4 2021 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
BriaCell Therapeutics Corp. quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and change rate from Q4 2021 to Q1 2023.
  • BriaCell Therapeutics Corp. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Apr 2023 was -$4.9M, a 51.1% increase year-over-year.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)

BriaCell Therapeutics Corp. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 -$4.9M +$5.12M +51.1% 01 Feb 2023 30 Apr 2023 10-Q 14 Jun 2023
Q4 2022 -$11.9M -$23M -206% 01 Nov 2022 31 Jan 2023 10-Q 16 Mar 2023
Q1 2022 -$10M 01 Feb 2022 30 Apr 2022 10-Q 14 Jun 2023
Q4 2021 $11.2M 01 Nov 2021 31 Jan 2022 10-Q 16 Mar 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.